Correlation Between Serum Alpha-Fetoprotein and Tumour Size in Patients With Hepatocellular Carcinoma Treated With Direct-Acting Antivirals.
direct-acting antivirals
hepatitis c virus (hcv)
hepatocellular carcinoma
serum alpha-fetoprotein
tumour burden score
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
accepted:
26
04
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Since its first description, alpha-fetoprotein has become the most widely used marker for diagnosing and monitoring patients with hepatocellular carcinoma (HCC). This study aims to assess the correlation between serum levels of alpha-fetoprotein and tumour dimensions in patients diagnosed with HCC, that were previously treated with direct-acting antivirals for hepatitis C viral infection. We conducted a retrospective cohort study on 47 patients with a personal history of hepatitis C virus infection, who were diagnosed with different forms of HCC more than one year after achieving sustained virologic response after 12 weeks post-treatment. Patients were monitored by liver function tests, tumoral markers, blood cell count and coagulation profile and underwent imagistic explorations such as abdominal ultrasonography and, in selected cases, computerised tomography/magnetic resonance imaging. Tumour burden was assessed by both tumour burden score and seven-eleven criteria. The study mostly included cirrhotic patients, multinodular HCC being the predominant pattern. All patients had alpha-fetoprotein levels over 100 ng/ml, with values largely varying, in accordance with the tumour dimensions. Most patients had medium-range Tumour Burden Score, a variable that also correlated with nodule size. The study found a significant correlation between serum alpha-fetoprotein and tumour size in patients with HCC. Alpha-fetoprotein also correlated well with Tumour Burden Score and remains a very important diagnostic and prognostic tool for patients with HCC.
Identifiants
pubmed: 35497085
doi: 10.7759/cureus.24506
pmc: PMC9045839
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e24506Informations de copyright
Copyright © 2022, Rusie et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
World J Gastroenterol. 2022 Jan 14;28(2):216-229
pubmed: 35110946
Clin Pract (Lond). 2018;15(1):453-464
pubmed: 29576865
Int J Health Sci (Qassim). 2016 Jan;10(1):121-36
pubmed: 27004063
Front Med (Lausanne). 2020 May 22;7:174
pubmed: 32528965
Gastroenterology. 2012 Oct;143(4):986-94.e3; quiz e14-5
pubmed: 22750200
Exp Ther Med. 2021 Jul;22(1):749
pubmed: 34035846
Gastroenterology. 2017 Oct;153(4):996-1005.e1
pubmed: 28642197
Clin Chem Lab Med. 2007;45(9):1169-79
pubmed: 17635075
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Gastroenterology. 2020 Jul;159(1):335-349.e15
pubmed: 32247694
Eur J Gastroenterol Hepatol. 2019 Jan;31(1):75-79
pubmed: 30199473
J Adv Res. 2019 Mar 07;17:43-48
pubmed: 31193326
Ann Intern Med. 2003 Jul 1;139(1):46-50
pubmed: 12834318
Cancers (Basel). 2021 Feb 11;13(4):
pubmed: 33670174
Semin Oncol. 2012 Aug;39(4):410-33
pubmed: 22846859
Liver Cancer. 2021 Jul 22;10(6):629-640
pubmed: 34950185
JAMA Surg. 2017 Jan 1;152(1):55-64
pubmed: 27706479
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Clin Liver Dis. 2015 May;19(2):309-23
pubmed: 25921665
Gastroenterology. 2015 Jul;149(1):190-200.e2
pubmed: 25754160
J Gastrointest Cancer. 2018 Dec;49(4):476-480
pubmed: 28920172
Am J Gastroenterol. 2000 Jun;95(6):1535-8
pubmed: 10894592